The FASEB Journal, Vol 4, 2745-2752, Copyright © 1990 by The Federation of American Societies for Experimental Biology

REVIEWS

Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?

AM Palmer and S Gershon
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, Pennsylvania 15213.

The hypothesis that the symptomatology of Alzheimer's disease is attributable to cholinergic dysfunction is supported by postmortem studies that have demonstrated reduced choline acetyltransferase (ChAT) activity across all areas of cerebral cortex and diminished numbers of perikarya in the basal forebrain nucleus basalis of Meynert. Biopsy studies of ChAT activity, choline uptake, and acetylcholine synthesis also suggest that cholinergic denervation occurs relatively early in the course of the disease, and in confirmation of postmortem data, correlates with the severity of cognitive impairment. An alternative hypothesis to explain the dementia of Alzheimer's disease is the glutamatergic hypothesis. This is based largely on postmortem evidence indicating reduced binding and uptake of D[3H]aspartate, as well as loss of a number of other putative markers, such as phosphate-activated glutaminase activity, glutamate concentration, and the number of pyramidal cell perikarya, with this latter change correlating with the severity of dementia. Short-comings of each hypothesis are discussed and the merits of single neuron hypotheses to explain the dementia of Alzheimer's disease are considered.

This article has been cited by other articles:

				G. T. Grossberg, K. R. Edwards, and Q. Zhao Rationale for Combination Therapy With Galantamine and Memantine in Alzheimer's Disease J. Clin. Pharmacol., July 1, 2006; 46(suppl_1): 17S - 26S. [Abstract] [Full Text] [PDF]

				S. Moriguchi, X. Zhao, W. Marszalec, J. Z. Yeh, and T. Narahashi Modulation of N-Methyl-D-aspartate Receptors by Donepezil in Rat Cortical Neurons J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 125 - 135. [Abstract] [Full Text] [PDF]

				S. Moriguchi, W. Marszalec, X. Zhao, J. Z. Yeh, and T. Narahashi Mechanism of Action of Galantamine on N-Methyl-D-Aspartate Receptors in Rat Cortical Neurons J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 933 - 942. [Abstract] [Full Text] [PDF]

				Q. Chen, H. Yoshida, D. Schubert, P. Maher, M. Mallory, and E. Masliah Presenilin Binding Protein Is Associated with Neurofibrillary Alterations in Alzheimer's Disease and Stimulates Tau Phosphorylation Am. J. Pathol., November 1, 2001; 159(5): 1597 - 1602. [Abstract] [Full Text] [PDF]

				J. J. Buccafusco and A. V. Terry Jr. Multiple Central Nervous System Targets for Eliciting Beneficial Effects on Memory and Cognition J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 438 - 446. [Abstract] [Full Text]

				C. C. Meltzer Neuropharmacology and Receptor Studies in the Elderly J Geriatr Psychiatry Neurol, October 1, 1999; 12(3): 137 - 149. [Abstract] [PDF]

				P. T Francis, A. M Palmer, M. Snape, and G. K Wilcock The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psychiatry, February 1, 1999; 66(2): 137 - 147. [Abstract] [Full Text]

				W. Danysz and C. G. Parsons Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664. [Abstract] [Full Text] [PDF]

				N. Matsuoka and T. G. Aigner FK960 [N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide Monohydrate], a Novel Potential Antidementia Drug, Improves Visual Recognition Memory in Rhesus Monkeys: Comparison with Physostigmine J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1201 - 1209. [Abstract] [Full Text]